40 results
Page 2 of 2
8-K
EX-99.1
iay50m ypeofe
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
8-K
EX-99.2
0ic4u2bh
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
424B5
67fkx47 g3yzf0edb
31 Jul 20
Prospectus supplement for primary offering
4:00pm
8-K
EX-99.1
evzf9ss8sa
30 Jul 20
Blueprint Medicines Reports Second Quarter 2020 Financial Results
7:38am
8-K
EX-99.1
e83679x82pxxo12td
14 Jul 20
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
6:27am
424B5
hxgeaug r139tf5q5apm
23 Jan 20
Prospectus supplement for primary offering
4:24pm
424B5
al242
21 Jan 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.1
ckapm3y
13 Jan 20
Regulation FD Disclosure
8:30am
8-K
EX-99.1
0oiz49n
5 Nov 19
Results of Operations and Financial Condition
7:16am
8-K
EX-99.1
mh6hm944qj50ie5bk
16 Oct 19
Entry into a Material Definitive Agreement
6:51am
8-K
EX-99.1
5yd5x3dx8h9 p9g9m
4 Jun 19
Regulation FD Disclosure
7:30am
DRS
en6ffa3uc3 o3ew
19 Feb 15
Draft registration statement
12:00am